A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma

References

• Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocrine Reviews. 1997;18(1):26–45. PMID:9034785.
   PubMed Web of Science ®Google Scholar
• Dow J K, deVere White R W. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 2000;55(6):800–806. doi:10.1016/S0090-4295(00)00457-X. PMID:10840080.
   PubMed Web of Science ®Google Scholar
• Nugent M A, Iozzo R V. Fibroblast growth factor-2. International Journal of Biochemistry & Cell Biology. 2000;32(3):263. doi:10.1016/S1357-2725(99)00133-8.
   PubMed Web of Science ®Google Scholar
• Ornitz D. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays. 2000;22(2):108–112.
   PubMed Web of Science ®Google Scholar
• Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Advances in Cancer Research. 1992;59:115–125. doi:10.1016/S0065-230X(08)60305-X.
   PubMed Web of Science ®Google Scholar
• Becker D, Meier C B, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J. 1989;8(12):3685–3691. PMID:2684645.
   PubMed Web of Science ®Google Scholar
• Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med. 1997;3(8):887–893.
   PubMed Web of Science ®Google Scholar
• Shih I M, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. Vivo. 1994;8(1):113–123.
   PubMedGoogle Scholar
• Scott G, Stoler M, Sarkar S, Halaban R. Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization. Journal of Investigative Dermatology, 1991;96(3):318–322. doi:10.1111/1523-1747.ep12465203. PMID:2002252.
   PubMed Web of Science ®Google Scholar
• Al-Alousi S, Barnhill R, Blessing K, Barksdale S. The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma. J Cutan Pathol. 1996;23(6):506–510. doi:10.1111/j.1600-0560.1996.tb01442.x. PMID:9001980.
   PubMed Web of Science ®Google Scholar
• Al-Alousi S, Carlson J A, Blessing K, Cook M, Karaoli T, Barnhill RL. Expression of basic fibroblast growth factor in desmoplastic melanoma. J Cutan Pathol. 1996;23(2):118–125. doi:10.1111/j.1600-0560.1996.tb01284.x. PMID:8721445.
   PubMed Web of Science ®Google Scholar
• Albino A P, Davis BM, Nanus DM. Induction of Growth Factor RNA Expression in Human Malignant Melanoma: Markers of Transformation. Cancer Res. 1991;51(18):4815–4820. PMID:1716514.
   PubMed Web of Science ®Google Scholar
• Halaban R, Kwon B S, Ghosh S, Delli Bovi P, Baird A. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 1988;3(2):177–186. PMID:3226725.
   PubMedGoogle Scholar
• Valesky M, Spang AJ, Fisher GW, Farkas DL, Becker D. Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Molecular Medicine. 2002;8(2):103–112. PMID:12080186.
   PubMed Web of Science ®Google Scholar
• Demana P H, Fehske C, White K, Rades T, Hook S. Effect of incorporation of the adjuvant Quil A on structure and immune stimulatory capacity of liposomes. Immunol Cell Biol. 2004;82(5):547–554. doi:10.1111/j.0818-9641.2004.01276.x.
   PubMed Web of Science ®Google Scholar
• Marciani D J, Press J B, Reynolds R C, Pathak AK, Pathak V, Gundy LE, Farmer JT, Koratich MS, May RD. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000;18(27):3141–3151. doi:10.1016/S0264-410X(00)00118-3. PMID:10856794.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takeshfta T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 1990;344(6269):873–875. doi:10.1038/344873a0. PMID:2184369.
   PubMed Web of Science ®Google Scholar
• Soltysik S, Wu J Y, Recchia J, Wheeler DA, Newman MJ, Coughlin RT, Kensil CR. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine. 1995, 13(15):1403–1410. doi:10.1016/0264-410X(95)00077-E. PMID:8578817.
   PubMed Web of Science ®Google Scholar
• Hong S, Ackerman AL, Virginia C, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88. doi:10.1111/j.1365-2567.2005.02268.x. PMID:16423043.
   PubMed Web of Science ®Google Scholar
• Morein F, Bengtsson K L. Functional aspects of iscoms. Immunol Cell Biol. 1998;76(4):295–299. doi:10.1046/j.1440-1711.1998.00756.x.
   PubMed Web of Science ®Google Scholar
• Andersen B M, Ohlfest J R. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett. 2012;325(2):155–164. doi:10.1016/j.canlet.2012.07.012. PMID:22809568.
   PubMed Web of Science ®Google Scholar
• Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol. 1993;150(5):2072–2080.
   PubMed Web of Science ®Google Scholar
• Copland MJ, Rades T, Davies NM. Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes. Int J Pharm. 2000;196(2):135–139. doi:10.1016/S0378-5173(99)00407-X. PMID:10699704.
   PubMedGoogle Scholar
• Demana PH, Davies NM, Vosgerau U, Rades T. Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method. Int J Pharm. 2004, 270(1-2):229–239. doi:10.1016/j.ijpharm.2003.10.020. PMID:14726138.
   PubMedGoogle Scholar
• Falo LD Jr, Kovacsovicsbankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med. 1995;1(7):649–653. doi:10.1038/nm0795-649. PMID:7585145.
   PubMed Web of Science ®Google Scholar
• York IA, Rock K L. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996;14(14):369–396. doi:10.1146/annurev.immunol.14.1.369. PMID:8717519.
   PubMedGoogle Scholar
• Jain RK, Carmeliet P. SnapShot: Tumor Angiogenesis. Cell. 2012;149(6):1408. doi:10.1016/j.cell.2012.05.025. PMID:22682256.
   PubMed Web of Science ®Google Scholar
• Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000;6(10):1160–1166. doi:10.1038/80506. PMID:11017149.
   PubMed Web of Science ®Google Scholar
• Wei Y Q, Huang M J, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, et al. Immunogene Therapy of Tumors with Vaccine Based on Xenopus Homologous Vascular Endothelial Growth Factor as a Model Antigen. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(20):11545–11550. doi:10.1073/pnas.191112198. PMID:11553767.
   PubMed Web of Science ®Google Scholar
• Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991;51(22):6180–184. PMID:1718597.
   PubMed Web of Science ®Google Scholar
• Murai N, Ueba T, Takahashi J A, Yang HQ, Kikuchi H, Hiai H, Hatanaka M, Fukumoto M. Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J Neurosurg. 1996;85(6):1072–1077. doi:10.3171/jns.1996.85.6.1072. PMID:8929497.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Zhao Y, Yang H, Tong A, Zhao C, Shi H, Li Y, Wang Z, Wei Y. Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts. J Cancer Res Clini Oncol. 2014;140(2):271–280. doi:10.1007/s00432-013-1547-5.
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol. 2007;34(6):555–565. doi:10.1053/j.seminoncol.2007.09.009. PMID:18083379.
   PubMed Web of Science ®Google Scholar
• Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res. 2001;61(19):7282–7290. PMID:11585767.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Ribatti D, Bruno M, Dammacco F. Angiogenesis and tumor progression in melanoma. Recenti Prog Med. 2000;91(11):581–587. PMID:11125952.
   PubMedGoogle Scholar
• Plum S M, Holaday J W, Ruiz A, Madsen JW, Fogler WE, Fortier AH. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine. 2000;19(9-10):1294–1303. doi:10.1016/S0264-410X(00)00210-3. PMID:11137269.
   PubMed Web of Science ®Google Scholar